BIAF
bioAffinity Technologies, Inc.NASDAQHealthcare$3.92-1.51%ClosedMarket Cap: $17.6M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.99
P/S
3.05
EV/EBITDA
-0.94
DCF Value
$-295.94
FCF Yield
-49.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
23.2%
Operating Margin
-171.6%
Net Margin
-242.0%
ROE
-385.2%
ROA
-136.0%
ROIC
-125.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.6M | $-3.1M | $-1.82 |
| FY 2025 | $6.2M | $-14.9M | $-8.66 |
| Q3 2025 | $1.4M | $-5.1M | $-4.74 |
| Q2 2025 | $1.3M | $-4.1M | $-5.07 |
Trading Activity
Insider Trades
View AllRios Robertodirector
SellThu Sep 25
Oppenheimer John J.director:
SellThu Sep 25
Reveles Xavier Trinidadofficer: Chief Operating Officer
SellTue Jan 14
GIRGENTI STEVENdirector, officer: Executive Chairman
SellTue Jan 14
Zannes Mariadirector, officer: President & CEO
SellTue Jan 14
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.81
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.